Summary & Overview
CPT 81420: Fetal Chromosomal Aneuploidy Genomic Sequence Analysis Panel
CPT code 81420 represents a genomic sequence analysis panel for detecting fetal chromosomal aneuploidy, including conditions such as trisomy 21 (Down syndrome) and monosomy X, through the analysis of circulating cell-free fetal DNA in maternal blood. This test is a cornerstone of modern prenatal screening, offering non-invasive, highly accurate detection of chromosomal abnormalities by targeting chromosomes 13, 18, and 21. The service is typically performed in a laboratory setting and is classified under Genomic Sequencing / Molecular Pathology.
Major national payers, including Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare, provide coverage for this procedure, reflecting its widespread clinical adoption and importance in prenatal care. Readers will gain insights into payer coverage policies, clinical benchmarks, and recent policy updates relevant to CPT code 81420. The publication also explores the clinical context of the code, its role in prenatal screening, and its relationship to other molecular pathology procedures. This summary provides a comprehensive overview for healthcare professionals, laboratory administrators, and policy analysts seeking to understand the national landscape for fetal chromosomal aneuploidy testing.
CPT Code Overview
CPT code 81420 is used for genomic sequence analysis panels that detect fetal chromosomal aneuploidy, such as trisomy 21 and monosomy X, by analyzing circulating cell-free fetal DNA in maternal blood. This test must include analysis of chromosomes 13, 18, and 21. The service is classified under Genomic Sequencing / Molecular Pathology and is typically performed in a laboratory setting (Place of Service 81). This code is central to prenatal screening for chromosomal abnormalities, providing critical information for maternal and fetal health management.
Clinical & Coding Specifications
Clinical Context
A pregnant woman presents for routine prenatal care. Her obstetrician recommends non-invasive prenatal testing (NIPT) to screen for common fetal chromosomal aneuploidies, such as trisomy 21 (Down syndrome), trisomy 18, and trisomy 13. The test involves collecting a blood sample from the mother, which is sent to a laboratory (Place of Service 81) for genomic sequence analysis of circulating cell-free fetal DNA. The laboratory analyzes chromosomes 13, 18, and 21 to detect potential chromosomal abnormalities. Results are interpreted by a qualified provider, such as a genetic counselor or medical geneticist, and discussed with the patient as part of her prenatal care workflow.
Coding Specifications
-
Modifiers:
- Modifier
26: Used to indicate the professional component of the service, such as interpretation and reporting by a physician or qualified healthcare professional. - Modifier
TC: Used to indicate the technical component, which covers the laboratory processing and analysis of the specimen.
- Modifier
-
Provider Taxonomies:
| Taxonomy Code | Specialty Name |
|---|---|
207SG0201X | Genetic Counselor, MS |
207SG0202X | Medical Geneticist |
207VG0400X | Obstetrics & Gynecology Physician |
207ZB0001X | Clinical Biochemical Geneticist |
207ZP0007X | Clinical Molecular Geneticist |
These specialties are typically involved in ordering, interpreting, or counseling for fetal chromosomal aneuploidy testing.
Related Diagnoses
-
Z36.0: Encounter for antenatal screening for chromosomal anomalies- Used when the patient is undergoing routine screening for fetal chromosomal abnormalities.
-
O35.1XX0: Maternal care for (suspected) chromosomal abnormality in fetus, not applicable or unspecified- Applied when there is suspicion of a chromosomal abnormality in the fetus, prompting further testing.
-
Z13.79: Encounter for other screening for genetic and chromosomal anomalies- Used for screening encounters not otherwise specified, including genetic and chromosomal anomaly tests.
-
O28.3: Abnormal ultrasonic finding on antenatal screening of mother- Relevant when an abnormal ultrasound prompts additional genetic testing.
-
Z36.89: Encounter for other specified antenatal screening- Used for antenatal screening encounters that do not fit into more specific categories.
-
O09.511: Supervision of elderly primigravida, first trimester- Applied when the patient is an older first-time pregnant woman, which may increase the risk for chromosomal anomalies and warrant screening.
Related CPT Codes
| CPT Code | Description |
|---|---|
81228 | Cytogenomic constitutional (genome-wide) microarray analysis |
81229 | Cytogenomic constitutional (genome-wide) microarray analysis; each additional microarray |
81479 | Unlisted molecular pathology procedure |
81507 | Fetal aneuploidy DNA sequence analysis of selected regions using maternal plasma |
81228and81229are used for genome-wide microarray analysis, which may be performed as an alternative or adjunct to targeted aneuploidy testing (81420).81479is an unlisted code for molecular pathology procedures, used when a test does not have a specific CPT code.81507is another code for fetal aneuploidy DNA sequence analysis, often used as an alternative to81420depending on the methodology and regions analyzed.
National Reimbursement Benchmarks
Nationally, the mean rate for CPT code 81420 among BUCA (average commercial) payers is $599.62, which is higher than the Medicare rate. Commercial payers such as Blue Cross Blue Shield, UnitedHealth Group, and Cigna all report mean rates above $600, with Aetna slightly lower at $559.07.
Rate dispersion varies significantly across payers. Cigna exhibits the widest spread, with a difference of $639.00 between its 75th and 25th percentiles, indicating substantial variability in contracted rates. In contrast, Aetna has the tightest range at $220.00, suggesting more consistent reimbursement levels. Blue Cross Blue Shield and UnitedHealth Group also show moderate dispersion, while BUCA's range is $318.42.
The table and chart below present a detailed breakdown of national mean rates and percentile values for each payer.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.